SCHEDULE: Vivo Funds Update Cidara Therapeutics Stake to 4.6%
Schedule 13G Amendment
Vivo Opportunity Fund Holdings and affiliates updated their passive stake in Cidara Therapeutics, Inc. to 4.6% of common stock.
Summary
- Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, beneficially own 1,175,796 shares of Cidara Therapeutics, Inc. common stock, representing 4.6% of the class.
- Vivo Opportunity Cayman Fund, L.P. and its general partner, Vivo Opportunity Cayman, LLC, beneficially own 135,629 shares of Cidara Therapeutics, Inc. common stock, representing 0.5% of the class.
- The total number of common shares issued and outstanding for Cidara Therapeutics, Inc. was 25,358,051 as of August 6, 2025, as reported in the Issuer's Form 10-Q filed on August 7, 2025.
- The filing is an Amendment No. 2 to Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of a passive ownership stake and does not contain information that would significantly alter sentiment towards the issuer.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing is a routine disclosure of a passive investment stake by an institutional investor in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the ownership structure.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive ownership stake by institutional investors.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement. |
| 08/06/2025 | Date as of which the number of outstanding common shares (25,358,051) was reported by the Issuer. |
| 08/07/2025 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC, disclosing outstanding shares. |
| 08/12/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Cidara Therapeutics, Vivo Opportunity Fund Holdings, Vivo Opportunity, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, CDTX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.